Our results indicate that biologically naïve patients and those receiving TNF-α inhibitors had lower angioma counts compared to those treated with IL-23 inhibitors (5.89 ± 5.53 and 5.06 ± 4.39 vs. 6.94 ± 7.00). This evidence concerns the gene TNF and hemangioma.